My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

BeyondSpring, Inc. - Ordinary Shares (NQ:BYSI)

1.900 -0.070 (-3.55%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 3, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BeyondSpring, Inc. - Ordinary Shares

< Previous 1 2 3 4 5 6 Next >

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

August 04, 2021

Gainers BeyondSpring (NASDAQ:BYSI) stock increased by 337.79% to $42.16 during Wednesday's pre-market session. The market value of their outstanding shares is at $1.6...

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

July 02, 2021

Gainers Odonate Therapeutics (NASDAQ:ODT)...

Via Benzinga

14 Biotech Stocks To Watch Over The Next 6 Months ↗

June 23, 2021

Biotechs are at the mercy of several make-or-break catalysts that invariably have a big impact on stocks. A case in point was the strong upside in Biogen Inc.'s (NASDAQ:...

Via Benzinga

BeyondSpring Inc. (BYSI) Q1 2021 Earnings Call Transcript ↗

June 16, 2021

BYSI earnings call for the period ending March 31, 2021.

Via The Motley Fool

Topics Earnings

The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs ↗

August 01, 2021

Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results....

Via Benzinga

Earnings Scheduled For June 16, 2021 ↗

June 16, 2021

Companies Reporting Before The Bell • BeyondSpring (NASDAQ:BYSI) is projected to report earnings for its first quarter. • Centogene (NASDAQ:CNTG) is estimated to...

Via Benzinga

BeyondSpring's Plinabulin US Application for Chemo-Induced Neutropenia Under Review ↗

June 01, 2021

The FDA has accepted for review BeyondSpring Inc's (NASDAQ: BYSI) marketing application seeking approval for the use of plinabulin in combination with...

Via Benzinga

The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes ↗

May 31, 2021

After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-...

Via Benzinga

BeyondSpring Inc. (BYSI) Q1 2021 Earnings Call Transcript ↗

April 30, 2021

BYSI earnings call for the period ending March 31, 2021.

Via The Motley Fool

Topics Earnings

Earnings Scheduled For April 30, 2021 ↗

April 30, 2021

Companies Reporting Before The Bell • O2Micro Intl (NASDAQ:OIIM) is estimated to report quarterly earnings at $0.09 per share on revenue of $23.30 million. • Twin...

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

April 21, 2021

Wednesday morning, 25 companies reached new 52-week lows. Intriguing Points: Lufax Holding (NYSE:LU) was the biggest company by market cap to set a new 52-week low...

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

April 16, 2021

Before 10 a.m. ET Friday, 62 stocks made new 52-week lows. Significant Points: The largest company by market cap to set a new 52-week low was Yatsen Holding (NYSE:...

Via Benzinga

BeyondSpring Files US-China Application For Plinabulin G-CSF Treatment In Chemo-Induced Neutropenia ↗

April 01, 2021

BeyondSpring Inc (NASDAQ: BYSI) has submitted marketing applications in the U.S. and China seeking approval for plinabulin in combination with granulocyte...

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.